Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)

China flag China · Delayed Price · Currency is CNY
37.20
-0.68 (-1.80%)
Apr 21, 2026, 3:00 PM CST
Market Cap15.09B +111.9%
Revenue (ttm)662.52M +231.6%
Net Income-969.33M
EPS-2.43
Shares Out398.41M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6,827,159
Average Volume9,693,366
Open37.82
Previous Close37.88
Day's Range36.72 - 38.20
52-Week Range16.78 - 63.59
Beta0.76
RSI49.00
Earnings DateMar 25, 2026

About SHA:688062

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection; and JUNMAIKANG, an autoimmune Adalimumab injection. It also provide... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 1,325
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688062
Full Company Profile

Financial Performance

In 2025, SHA:688062's revenue was 662.52 million, an increase of 231.62% compared to the previous year's 199.78 million. Losses were -969.33 million, -7.14% less than in 2024.

Financial Statements